Redox-Responsive Polyphosphoester-Based Micellar Nanomedicines for Overriding Chemoresistance in Breast Cancer Cells

• DOI: 10.1021/acsami.5b09195
• Publication Date: 2015-11-10T11:10:37Z
• Authors: Yin-Chu Ma; Jun-Xia Wang; Wei Tao; Chun-Yang Sun; Yu-Cai Wang; Dong-Dong Li; Feng Fan; Hai-Sheng Qian; Xian-Zhu Yang
• Keywords: Mice, Inbred BALB C; Cell Death; Cell Survival; Mice, Nude; Antineoplastic Agents; Breast Neoplasms; Esters; 02 engineering and technology; Flow Cytometry; Drug Resistance, Multiple; Dynamic Light Scattering; 3. Good health; Nanomedicine; Doxorubicin; Drug Resistance, Neoplasm; Cell Line, Tumor; Animals; Humans; Female; 0210 nano-technology; Oxidation-Reduction; Micelles; Cell Proliferation

Multidrug resistance (MDR) has been recognized as a key factor contributing to the failure of chemotherapy for cancer in the clinic, often due to insufficient delivery of anticancer drugs to target cells. For addressing this issue, a redox-responsive polyphosphoester-based micellar nanomedicine, which can be triggered to release transported drugs in tumor cells, has been developed. The micelles are composed of diblock copolymers with a hydrophilic PEG block and a hydrophobic polyphosphoester (PPE) block bearing a disulfide bond in a side group. After incubating the redox-responsive micelles with drug-resistant tumor cells, the intracellular accumulation and retention of DOX were significantly enhanced. Moreover, after internalization by MDR cancer cells, the disulfide bond in the side group was cleaved by the high intracellular glutathione levels, resulting in a hydrophobic to hydrophilic transition of the PPE block and subsequent disassembly of the micelles. Thus, the encapsulated DOX was rapidly released, and abrogation of drug resistance in the cancer cells was observed in vitro. Moreover, the DOX-loaded redox-responsive micelles exhibited significantly enhanced inhibition of tumor growth in nude mice bearing MCF-7/ADR xenograft tumors via tail vein injection, indicating that such micelles have great potential in overcoming MDR for cancer therapy.